Programme

Download


BOS Basel 2024 Programme

BOS Basel 2024's scope is primarily development-stage CMC outsourcing for both Small Molecules and Biologics, as well as covering Novel Therapeutic Entities.

We have a single-track programme consisting of high-quality presentations and drawing from the diverse organisation types in the community including multinational pharmaceutical companies, speciality pharma, SME biotech, CRO/CMO and Consultants. Our programme consists of the following modules:

Outsourcing Business Process
Exploring strategies and processes driving sourcing and procurement of R&D services

Technical Operations
Exploring the technical elements of outsourcing discovery R&D, Drug Substance Outsourcing, Analytical Development Outsourcing, Drug Product Outsourcing for Biologics and Small Molecules.

Outsourcing Case Studies
Building on the Technical Operations sessions, demonstrating outsourcing approaches to real life scenarios.

Share this page

Day 1 - 19th June 2024

Time BOS Basel Programme
08:00 - 09:00
Registration and Partnering
09:00 - 10:30 Outsourcing Process and Strategy
09:00 - 09:30
Designing a Scalable Biologics Outsourcing Strategy for a Fast Growing International Biotech Company
Mr Jesper Valbjørn, SVP, Global CMC Operations, Genmab A/S
photo of Jesper Valbjørn
About the speaker


Full Speaker profile

09:30 - 10:00
AI - The Future of the Outsourcing Partnerships?
Dr Tarita Qveflander, Head of Strategic Sourcing and Direct Procurement, Swedish Orphan Biovitrum AB
photo of Tarita Qveflander
About the speaker

Tarita Qveflander is the Head of Strategic Sourcing and Direct Procurement at Sobi – Swedish Orphan Biovitrum AB. Tarita has 18+ years of pharmaceutical operations, supply chain, and procurement experience. She also has extensive knowledge of global API/drug substance, drug product, and finished goods supply chain, including hands-on technical expertise and a deep understanding of quality and GMP regulations.
Full Speaker profile

10:00 - 10:30
Managing the Transition to a Sustainable Sourcing Strategy: Gabrielle Sassi, Head of Sustainable and Global Research and Technical Development Outsourcing Management & Elena Bosi, Global CMC Outsourcing Manager, Chiesi
10:30 - 11:00
Coffee and Partnering
11:00 - 12:00 Outsourcing Case Studies
11:00 - 11:20
In-house Manufacture or External Sourcing of Gene Editing Reagents to Support the Growing Cell and Gene Therapy Business
Dr Ulrich Rümenapp, Senior Program Lead, Bayer AG
photo of Ulrich Rümenapp
About the speaker

Dr. Rümenapp is based in Wuppertal, Germany and working within the Product Supply Biotech organization of Bayer AG, where he is responsible for the transfer of Bayer’s pipeline candidates (antibodies and antibody-drug-conjugates) to external manufacturing partners and regulatory submission and launch preparations.

Prior to working in Development, Dr. Rümenapp was Head of Biotech Projects in Product Supply Biotech at Bayer, where he was responsible for contract manufacturing partnerships in the field of biotechnological drug substances and drug products and interdisciplinary project management with the goal to ensure market supply. Before it was acquired by Bayer, Dr. Rümenapp hold a similar position at Schering AG, and before that, he worked in the Production & Logistics department of Schering, where he was responsible for production aspects of in- and out-licensing deals, due diligences, and product acquisitions of small molecule products and biologics.Dr. Rümenapp studied chemistry and holds a Ph.D. in biosciences. He worked several years in academic research in the field of signal transduction and as an assistant teacher in the field of general pharmacology.Today, Dr. Rümenapp area of expertise is the set-up and management of external relationships for the development and supply of bio-pharmaceutical products. He has more than 20 years of experience in the bio-pharmaceutical industry.To correspond with Dr. Rümenapp, please contact him at [email protected].
Full Speaker profile

11:20 - 11:40
Gold Sponsor : Axplora - Presentation Title to be Confirmed
11:40 - 12:00
Presentation Title to be Confirmed
12:00 - 13:30
Lunch and Partnering
13:30 - 15:30 Technical Operations Outsourcing
13:30 - 14:00
Chemical Development of Remibrutinib
Dr Lucie Lovelle, Associate Director, Science and Technology, Novartis
photo of Lucie Lovelle
About the speaker


Full Speaker profile

14:00 - 14:30
Presentation Title to be Confirmed
Dr Werngard Czechtizky, Head Medicinal Chemistry, AstraZeneca
photo of Werngard Czechtizky
About the speaker

Werngard Czechtizky obtained her PhD at ETH Zürich. After a postdoctoral stay at Harvard University, she worked on GPCR lead generation in a global Chemical Biology platform at Aventis. At Sanofi, from 2005, she moved into a parallel synthesis team working in the fields of CNS and CV diseases. In 2010, she became leader of a Medicinal Chemistry section working on Diabetes programs. In 2014, she was appointed Head of Chemistry at Sanofi R&D Germany, with therapeutic focus on Diabetes, pain and inflammatory indications. Since 2017, she is Head of Medicinal Chemistry, Respiratory, Inflammation and Autoimmunity, at AstraZeneca in Sweden.
Full Speaker profile

14:30 - 15:00
Sourcing Radiopharmaceutical Manufacturing Expertise
Mr Dimitrios Mantzilas, CTO, Precirix
photo of Dimitrios Mantzilas
About the speaker

Passionate about advancing healthcare through radiopharmaceuticals

As a dedicated professional and pioneer in the field of radiopharmaceuticals, I bring a wealth of experience and expertise in the dynamic intersection of nuclear medicine and pharmaceuticals. My mission is to contribute to the advancement of healthcare by leveraging the power of radiopharmaceuticals to diagnose and treat diseases.

Over the years, I have been at the forefront of cutting-edge research, development, and production of radiopharmaceuticals that play a pivotal role in personalized medicine. I thrive on the challenges of innovating within a rapidly evolving industry, always seeking novel solutions to enhance diagnostic accuracy and therapeutic efficacy.

Having successfully navigated the complexities of regulatory frameworks, I have a proven track record of bringing radiopharmaceuticals from concept to market. My commitment to excellence extends beyond the laboratory, as I actively engage in industry conferences, share insights, and collaborate with professionals to stay ahead of the curve.

Let's connect to explore opportunities for collaboration, knowledge exchange, and mutually beneficial partnerships. Together, let's drive innovation in radiopharmaceuticals to make a lasting impact on patient outcomes and contribute to the future of healthcare.
Full Speaker profile

15:00 - 15:15
Where are the polymorph reference samples ?
Dr Pierric Marchand, CEO, Holodiag
15:15 - 15:30
Gold Sponsor : Ardena - Presentation Title to be Confirmed
15:30 - 16:00
Coffee and Partnering
16:00 - 17:00 Outsourcing Case Studies
16:00 - 16:20
Outsourcing of API and Formulation Manufacturing of a Compound with Segregation Needs.
Dr Yogeshwar Bachhav, Director (Consultant), AiCuris Anti-infective Cures AG
About the speaker


Full Speaker profile

16:20 - 16:40
A Novel Series of Ivosidenib-Polymer Cocrystals
Dr Adam Patterson, Senior Scientist I, Veranova
photo of Adam Patterson
About the speaker

Adam Patterson is an experienced research scientist with a demonstrated history of working in the pharmaceutical industry. Since joining Veranova in July 2016, Adam has both undertaken and led projects applying his expertise in solid state science to numerous active pharmaceutical ingredients. His work at Veranova covers polymorph screening, salt and cocrystal selection and crystallization development. Adam leads Veranova’s efforts in Raman spectroscopy with expertise in Raman mapping of drug products and also applies his skillset to the single crystal X-ray diffraction group, focusing on the structure solution of different solid forms of active pharmaceutical ingredients. Adam gained his PhD in Inorganic Chemistry from Trinity College Dublin, Ireland and an MChem from Durham University.
Full Speaker profile

16:40 - 17:00
Acquiring ADC Manufacturing Capacities and Capabilities: Insights from an Outsourcing Career
Dr Firelli Alonso, Consultant, ConsultFi Biologics, LLC
About the speaker


Full Speaker profile

17:00 - 19:00
Drinks Reception
Time BOS Basel Programme
08:00 - 09:00
Refreshments and Partnering
09:00 - 11:00 Technical Operations Outsourcing
09:00 - 09:30
Development of a Scalable Route toward an Alkylated 1,2,4-Triazol
Dr Raffael Davenport, Director, Team Leader Process Chemistry, Idorsia Pharmaceuticals Ltd.
About the speaker


Full Speaker profile

09:30 - 10:00
External Data Management Challenges and Strategies
Mr Mike Hindson, Scientific Externalisation SME, GSK
photo of Mike Hindson
About the speaker

I have worked within the pharmaceutical industry for over 30 years in R&D and previously manufacturing. A time-served analytical chemist who has been externalising development projects for over 20 years. Externalisation Subject Matter Expert with evolving expertise in Data Integrity with particular application in risk assessment of third party systems. Experience in technical delivery of pharma development projects from a diversity of global suppliers. Increasingly interested in using technology solutions to achieve efficient data transfer mechanisms and to deliver dynamic data from the supplier.
Full Speaker profile

10:00 - 10:30
10:30 - 10:45
Numaswitch: A Revolutionary Platform for Peptide, Peptein, and Protein Production
Dr Roxann Guerrette, Director, Numaferm
10:45 - 11:00
Gold Sponsor APC
11:00 - 11:30
Coffee and Partnering
11:30 - 12:30 Outsourcing Case Studies
11:30 - 11:50
Developing Novel siRNA Therapeutics and the Importance of Building Productive C(D)MO Partnerships
Dr Ioannis Giannios, Project Manager, Silence Therapeutics
photo of Ioannis Giannios
About the speaker

Ioannis Giannios is a Project Manager at Silence Therapeutics. Ioannis has worked for the last years as Project Manager in the biopharmaceutical area, focusing on development of Oligonucleotides as Drug Substance and Drug Product. He has extensive experience on management of late-stage and commercial projects, selection and establishment of CMO relationships and deep understanding of quality and GMP regulations.
Full Speaker profile

11:50 - 12:10
Gold Sponsor to be Confirmed
12:10 - 12:30
Navigating complexity of Cell and Gene Therapy Development and Outsourcing
Dr Grace Lee, Founder (Consultant), Elevalue Consulting LLC
About the speaker


Full Speaker profile

12:30 - 14:00
Lunch and Partnering
14:00 - 15:00 Panel Session: New Technologies Shaping External Manufacturing
Chair: Dr Joan Herbert, Vice President, Business Development, Medicines for Malaria Venture
Dr Christoph Becker, CEO and Partner, NegotiumBio GmbH
Mr Andre Unglert, Director Commercial Development Bioconjugates, Lonza AG
Dr Samanta Cimitan, CEO, Celonic Group, Celonic Group
About the speakers
Andre Unglert     
About the speaker


Full Speaker profile

Samanta Cimitan     
About the speaker

Samanta Cimitan PhD has been Chief Executive Officer at Celonic Group, a Pure Play Mammalian Biologics CDMO since August 2023. Sam has nearly 2 decades of experience in the specialty chemicals and life science industry, having worked for global organizations such as Ciba Specialty Chemicals, BASF and 13 years for Lonza. Prior to joining Celonic, she was Vice President at Lonza Pharma and Biotech Technical Operations.

Full Speaker profile

15:00 - 16:00
Conference Close and Drinks Reception